公开(公告)号：US20220002432A1

公开(公告)日：2022-01-06

申请号：US17293258

申请日：2019-11-15

Applicant: Virtuoso BINco, Inc. ,  The Regents of the University of California

Inventor： Bin LIU ,  Xiaocheng CHEN ,  Scott BIDLINGMAIER ,  Leonard POST ,  Yang SU ,  Namkyung LEE

IPC: C07K16/28 ,  A61K45/06

Abstract: Disclosed herein are anti-CD38 antibodies, anti-ICAM1 antibodies, pharmaceutical compositions comprising anti-CD38 antibodies and/or anti-ICAM1 antibodies, and methods of use for the treatment of a proliferative disease. In certain embodiments, also disclosed herein are multi-specific antibodies (e.g., bispecific antibodies) comprising a first targeting moiety that specifically binds to CD38 and a second targeting moiety that specifically binds to ICAM1, pharmaceutical compositions comprising the multi-specific antibodies, and methods of use for the treatment of a proliferative disease.

公开(公告)号：US20240076399A1

公开(公告)日：2024-03-07

申请号：US18183042

申请日：2023-03-13

Applicant: The Regents of the University of California

Inventor： Bin LIU ,  Namkyung LEE ,  Yang SU ,  Scott BIDLINGMAIER

IPC: C07K16/30 ,  A61K31/713 ,  C07K16/28 ,  C07K16/46

CPC classification number: C07K16/30 ,  A61K31/713 ,  C07K16/2821 ,  C07K16/2866 ,  C07K16/468 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

Abstract: The present disclosure relates to an engineered antibody that co-engages a cell type-selective (or specific) antigen (guide) and a signaling receptor (effector) on a target cell. In some instances, the engineered antibody is capable of modulating a signaling pathway on a target cell. In other embodiments, an engineered antibody of the present disclosure is administered to a subject for the treatment of a disease or condition.